Company intelligence / Profile preview

东莞安好医药科技

Dongguan, Guangdong, China

Ownership: Private
Development stage: Other

Overview

东莞安好医药科技有限公司 (Dongguan Anhao Pharmaceutical Technology) is a clinical-stage Chinese biotechnology company focused on developing novel targeted small-molecule therapeutics for oncology. The company's lead candidate is DX1002, an orally administered vascular-disrupting agent (VDA) that acts as a tubulin and CDH5 inhibitor to selectively destroy tumor vasculature. DX1002 is currently being evaluated in Phase 1b/2a clinical trials for advanced solid tumors, including hepatocellular carcinoma (HCC) and gastric cancer. The company operates in close collaboration with Guangzhou Anhao Pharmaceutical Technology and Dongguan Daxin Biotechnology to advance its oncology pipeline.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Guangzhou Anhao Pharmaceutical Technology Co., Ltd.Dongguan Daxin Biotechnology Co., Ltd.

Beyond the preview

Go deeper on 东莞安好医药科技.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 东莞安好医药科技.

Explore the full profile